Kian Behbakht
Overview
Explore the profile of Kian Behbakht including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1956
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nguyen L, Watson Z, Ortega R, Woodruff E, Jordan K, Iwanaga R, et al.
bioRxiv
. 2023 Mar;
PMID: 36865165
Euchromatic histone lysine methyltransferases 1 and 2 (EHMT1/2), which catalyze demethylation of histone H3 lysine 9 (H3K9me2), contribute to tumorigenesis and therapy resistance through unknown mechanisms of action. In ovarian...
12.
McMellen A, Yamamoto T, Qamar L, Sanders B, Nguyen L, Ortiz Chavez D, et al.
Mol Cancer Res
. 2022 Sep;
21(1):3-13.
PMID: 36149636
Implications: This study highlights that a novel p38-ATF6-mediated AP-1 signaling axis contributes to PARPi resistance and provides a clinical rationale for combining PARPi and AP-1 signaling inhibitors.
13.
Armstrong D, Alvarez R, Backes F, Bakkum-Gamez J, Barroilhet L, Behbakht K, et al.
J Natl Compr Canc Netw
. 2022 Sep;
20(9):972-980.
PMID: 36075393
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines...
14.
Yamamoto T, Webb P, Davis D, Baumgartner H, Woodruff E, Guntupalli S, et al.
Mol Cancer Ther
. 2022 Apr;
21(4):647-657.
PMID: 35373300
High-grade serous ovarian cancer is the deadliest gynecologic malignancy due to progression to resistant disease. Claudin-4 is classically defined as a tight junction protein and is often associated with epithelial...
15.
Haag J, Sanders B, Keach J, Lefkowits C, Sheeder J, Behbakht K
Gynecol Oncol Rep
. 2022 Feb;
39:100935.
PMID: 35141387
Biases in application review may limit access of applicants who are underrepresented in medicine (URM) to graduate medical training opportunities. We aimed to evaluate the association between blinding interviewers to...
16.
Clauset A, Behbakht K, Bitler B
Sci Adv
. 2021 Jun;
7(23).
PMID: 34088677
An opportunity to improve cancer outcomes with machine learning.
17.
Armstrong D, Alvarez R, Bakkum-Gamez J, Barroilhet L, Behbakht K, Berchuck A, et al.
J Natl Compr Canc Netw
. 2021 Feb;
19(2):191-226.
PMID: 33545690
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. A...
18.
Jordan K, Sikora M, Slansky J, Minic A, Richer J, Moroney M, et al.
Clin Cancer Res
. 2020 Sep;
26(23):6362-6373.
PMID: 32928797
Purpose: Ovarian cancer has one of the highest deaths to incidence ratios across all cancers. Initial chemotherapy is effective, but most patients develop chemoresistant disease. Mechanisms driving clinical chemo-response or...
19.
Corr B, Moroney M, Sheeder J, Eckhardt S, Sawyer B, Behbakht K, et al.
Cancer
. 2020 Jul;
126(19):4289-4293.
PMID: 32697381
Background: Patients with ovarian cancer who are enrolled on phase 1 trials typically have platinum-resistant and heavily pretreated disease, with a poor prognosis. In the current study, the authors assessed...
20.
Johnson S, Renz M, Wheeler L, Diver E, Dorigo O, Litkouhi B, et al.
Int J Gynecol Cancer
. 2020 Jul;
30(8):1118-1123.
PMID: 32641392
Objective: Vulvar cancers account for 5% of all gynecologic malignancies; only 1%-3% of those vulvar cancers are primary vulvar sarcomas. Given the rarity of vulvar sarcomas, outcome data specific to...